This content is only available within our institutional offering.

14 Nov 2018
Rude Health - finnCap Life Sciences quarterly sector note
Allergy Therapeutics plc (AGY:LON), 7.6 | Bioventix Plc (BVXP:LON), 2,700 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | OptiBiotix Health PLC (OPTI:LON), 11.2 | SDI Group plc (SDI:LON), 91.5 | Tristel Plc (TSTL:LON), 425 | Destiny Pharma Plc (DTTYF:OTC), 0

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Rude Health - finnCap Life Sciences quarterly sector note
Allergy Therapeutics plc (AGY:LON), 7.6 | Bioventix Plc (BVXP:LON), 2,700 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | OptiBiotix Health PLC (OPTI:LON), 11.2 | SDI Group plc (SDI:LON), 91.5 | Tristel Plc (TSTL:LON), 425 | Destiny Pharma Plc (DTTYF:OTC), 0
- Published:
14 Nov 2018 -
Author:
Mark Brewer -
Pages:
32 -
AIM Healthcare Index fell 10% in the past three months, compared with an 8.5% decline in the FT AIM All Share. The performance stats in the past month were more balanced, with AIM Health down 1.5% compared with a 3% decline in the AIM All Share. Despite this, ten finnLife 50 stocks showed positive gains with four rising by 15%+: namely Tiziana Life Sciences (+89% – FDA clearance to start Phase I trial with foralumab, an orally delivered antibody, and the announced intention to IPO on NASDAQ); Sinclair Pharma (+46% – agreed takeover); Omega Diagnostics (+28% – strategic update); and Creo Medical (+28% – product launch). Conversely, Diurnal shares fell c.80% on the back of a failed Phase III trial for Chronocort in chronic adrenal hyperplasia